Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study
, , , , , , und
14. Aug. 2022
Über diesen Artikel
Artikel-Kategorie: research article
Online veröffentlicht: 14. Aug. 2022
Seitenbereich: 371 - 379
Eingereicht: 31. Jan. 2022
Akzeptiert: 07. Apr. 2022
DOI: https://doi.org/10.2478/raon-2022-0025
Schlüsselwörter
© 2022 Nina Turnsek, Rok Devjak, Natalija Edelbaher, Ilonka Osrajnik, Mojca Unk, Dusanka Vidovic, Tina Jeric, Urska Janzic, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Turnsek, Nina
Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Devjak, Rok
Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Edelbaher, Natalija
Department of Pulmonary Diseases, University Medical Centre MariborPohorje, Slovenia
Osrajnik, Ilonka
Department of Pulmonary Diseases, University Medical Centre MariborPohorje, Slovenia
Unk, Mojca
Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Vidovic, Dusanka
Department of Pulmonary Diseases, University Medical Centre MariborPohorje, Slovenia
Jeric, Tina
AstraZeneca UK Limited, Branch office in SloveniaLjubljana, Slovenia
Janzic, Urska
Department of Medical Oncology, University Clinic GolnikGolnik, Slovenia